GLP-1 receptor agonists (GLP-1 RAs) are associated with a 35% reduction in myocardial infarction and a 22% reduction in ischemic stroke in T2D patients with retinopathy.
Ocular protection: The use of GLP-1 RAs reduced the risk of progression to proliferative diabetic retinopathy (PDR) by 22% and retinal vein occlusions (RVO) by 30%.
Renal benefits were profound, with a 60% reduction in the need for renal replacement therapy (RRT).
The data suggest GLP-1 RAs do not increase the risk of NAION or retinal artery occlusions, addressing long-standing clinical concerns.
